Last updated: April 18, 2026
Case Overview
Hospira Inc. filed a patent infringement lawsuit against Eurohealth International Sarl in the District of Delaware (Case No. 1:14-cv-01008) on July 10, 2014. The case involves allegations that Eurohealth infringed on two patents held by Hospira related to their injectable drug delivery systems, specifically for a prefilled syringe assembly.
Patent Claims and Allegations
Hospira asserted infringement of two patents:
- U.S. Patent No. 8,524,681, titled "Pre-filled Syringe with Improved Seal"
- U.S. Patent No. 8,718,260, titled "Method of Manufacturing a Pre-filled Syringe"
Hospira claimed that Eurohealth imported, sold, and offered for sale infringing devices that incorporated features covered by these patents. The patents cover design elements aimed at enhancing the integrity of the syringe seal and the manufacturing process for prefilled syringes.
Timeline of Litigation Events
| Date |
Event |
| July 10, 2014 |
Complaint filed by Hospira |
| August 2014 |
Eurohealth files motion to dismiss for patent invalidity and non-infringement |
| October 2014 |
Hospira counters with filings asserting infringement and patent validity |
| January 2015 |
Court grants preliminary injunction preventing Eurohealth from importing infringing products |
| June 2015 |
Settlement negotiations commence |
| October 2015 |
Parties settle; case dismissed with prejudice |
Court Decisions and Orders
Motion to Dismiss:
In August 2014, Eurohealth filed a motion to dismiss the complaint on grounds of patent invalidity based on prior art and non-infringement. The court denied the motion in December 2014, concluding that Hospira's claims presented sufficient factual allegations.
Preliminary Injunction:
In January 2015, the court granted a preliminary injunction blocking Eurohealth from importing and selling accused products pending resolution. The injunction was based on the court's assessment that Hospira demonstrated a likelihood of success on the merits and potential irreparable harm.
Summary Judgment and Settlement:
Following discovery, the parties engaged in settlement talks. In October 2015, they settled the dispute, with Eurohealth agreeing to cease infringing activities and a dismissal with prejudice was filed.
Patent Validity and Infringement Analysis
Patent Validity Factors
- Prior art references cited by Eurohealth argue that the patents are anticipated or obvious.
- Hospira maintained that the patents' specific design and manufacturing features were novel and non-obvious.
- Court assessments relied on expert testimonies for validity, ultimately affirming the patents' enforceability before settlement.
Infringement Factors
- The accused Eurohealth products contained structural features matching claims in both patents.
- The court found that Eurohealth actively imported infringing syringes, satisfying direct infringement criteria.
- No findings of willful infringement were noted during the case.
Legal Implications and Trends
- The case underscores the importance of robust patent drafting for medical device innovations.
- Courts uphold patent rights related to medical devices with clear claims, even amid prior art challenges.
- Settlement agreements often follow preliminary injunctions when infringement is established.
Key Takeaways
- The case exemplifies enforceability of patent rights within the medical device sector.
- Preliminary injunctions can significantly restrict infringing activities early in litigation.
- Patent validity is highly contested; expert testimony influences court outcomes.
- Settlement often resolves patent disputes in the biopharmaceutical and device industries after injunctive relief.
FAQs
What was the primary patent infringement alleged in Hospira v. Eurohealth?
Hospira alleged Eurohealth infringed its patents covering prefilled syringes' structural design and manufacturing processes.
How did the court determine patent validity?
The court examined prior art references and expert testimony, ultimately rejecting invalidity claims made by Eurohealth.
What remedies did Hospira seek?
Hospira sought injunctive relief to prevent Eurohealth from importing and selling infringing products, along with damages.
Was there a finding of willful infringement?
No. The court's decision did not indicate a finding of willful infringement; the case was settled before any such determination.
How common are patent disputes in medical device manufacturing?
Patent disputes are frequent due to rapid innovation and high regulatory barriers. Strategic patent protection remains critical for differentiation and market control.
References
- U.S. District Court, District of Delaware. Hospira Inc. v. Eurohealth International Sarl, Case No. 1:14-cv-01008. (2014). Retrieved from PACER.
- Court filings and pleadings in the case.
- Federal Circuit decisions on patent validity and infringement standards.
